Bedaquiline monotherapy may be effective at improving multibacillary leprosy.
1. In this proof-of-concept study, bedaquiline therapy cleared Mycobacterium leprae by four weeks of treatment in patients with multibacillary leprosy. ...
Tag: immunology
Twice-yearly lenacapavir prevents HIV more effectively than daily F/TDF or F/TAF
1. In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir resulted in ...
Axatilimab reduces symptoms in patients with graft versus host disease
1. In this randomized controlled trial, axatilimab effectively managed symptoms in patients with recurrent or refractory graft versus host disease ...
Benralizumab associated with histologic response in eosinophilic esophagitis
1. In this randomized controlled trial, benralizumab, an anti-interleukin-5 receptor (anti-IL-5R) monoclonal antibody, demonstrated histologic depletion of eosinophils among patients ...
Serum interleukins may be elevated in patients with obsessive-compulsive disorder
1. Serum interleukin-1β (IL-1β) and interleukin-6 (IL-6) levels were higher in obsessive-compulsive disorder (OCD) patients compared to healthy controls. Evidence ...
Anti-CD38 monoclonal antibody improves platelet counts in immune thrombocytopenia
1. In this randomized controlled trial, CM313, an anti-CD38 monoclonal antibody therapy, was associated with rapid recovery of platelet counts ...
Benralizumab noninferior to mepolizumab for eosinophilic granulomatosis with polyangiitis
1. In this randomized controlled trial, benralizumab was noninferior for beginning remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) ...
Seladelpar improves symptoms of primary biliary cholangitis
1. In this randomized controlled trial, among patients with primary biliary cholangitis (PBC) who had had inadequate response to ursodeoxycholic ...
Elafibranor associated with biochemical response in patients with primary biliary cholangitis
1. In this randomized controlled trial, primary biliary cholangitis (PBC) patients who received elafibranor had significantly improved serum markers of ...
Immune checkpoint inhibitors may increase risk of atherosclerotic cardiovascular disease
1. In patients diagnosed with stage III or IV non-small cell lung cancer (NSCLC), immune checkpoint inhibitors were associated with ...